QSAR models for predicting enzymatic hydrolysis of new chemical entities in 'soft-drug' design.

The work described here is aimed at developing QSAR models capable of predicting in vitro human plasma lability/stability. They were built based on a dataset comprising about 200 known compounds. 3D structures of the molecules were drawn, optimized and submitted to the calculation of molecular descriptors that enabled selecting different TR/TS set pairs, subsequently exploited to develop QSAR models. Several 'machine learning' algorithms were explored in order to obtain suitable classification models, which were then validated on the relevant TS sets. Moreover the predictive ability of the best performing models was assessed on a Prediction set (PS) comprising about 40 molecules, not strictly related, from a structural point of view, to the initial dataset, but (obviously) comprised within the validity domain of the QSAR models obtained. The study allowed selecting predictive models enabling the classification of New Chemical Entities with regard to hydrolysis rate, that may be exploited for soft-drug design.

[1]  C. Tralau-Stewart,et al.  Novel Glucocorticoid Antedrugs Possessing a 17β-(γ-Lactone) Ring , 2001 .

[2]  P Willett,et al.  Comparison of algorithms for dissimilarity-based compound selection. , 1997, Journal of molecular graphics & modelling.

[3]  Brian D. Hudson,et al.  Parameter Based Methods for Compound Selection from Chemical Databases , 1996 .

[4]  B. Vig,et al.  Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs , 2005, Molecular Cancer Therapeutics.

[5]  S. Larsen,et al.  Kinetics of degradation and oil solubility of ester prodrugs of a model dipeptide (Gly-Phe). , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .

[7]  T. Aboul-Fadl,et al.  Metronidazole twin ester prodrugs : synthesis, physicochemical properties, hydrolysis kinetics and antigiardial activity , 1998 .

[8]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[9]  Roberto Todeschini,et al.  Handbook of Molecular Descriptors , 2002 .

[10]  A. Francisco,et al.  Triazene drug metabolites. Part 17: Synthesis and plasma hydrolysis of acyloxymethyl carbamate derivatives of antitumour triazenes. , 2000, Bioorganic & medicinal chemistry.

[11]  Igor V. Tetko,et al.  Virtual Computational Chemistry Laboratory – Design and Description , 2005, J. Comput. Aided Mol. Des..

[12]  C. A. Ventura,et al.  In vitro evaluation of quercetin-3-O-acyl esters as topical prodrugs. , 2007, International journal of pharmaceutics.

[13]  Ramaswamy Nilakantan,et al.  Database diversity assessment: New ideas, concepts, and tools , 1997, J. Comput. Aided Mol. Des..

[14]  Alessandro Pedretti,et al.  VEGA – An open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming , 2004, J. Comput. Aided Mol. Des..

[15]  Sally Freeman,et al.  Synthesis, characterization and stability of dendrimer prodrugs. , 2006, International journal of pharmaceutics.

[16]  G. Giorgioni,et al.  Dimeric L-dopa derivatives as potential prodrugs. , 2001, Bioorganic & medicinal chemistry letters.

[17]  S. Frokjaer,et al.  Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[18]  A. Hernández-Campos,et al.  Synthesis and hydrolytic stability studies of albendazole carrier prodrugs. , 2001, Bioorganic & medicinal chemistry letters.

[19]  Andrew W. Moore,et al.  Locally Weighted Learning , 1997, Artificial Intelligence Review.

[20]  B Testa,et al.  Esters of L‐Dopa: Structure‐hydrolysis Relationships and Ability to Induce Circling Behaviour in an Experimental Model of Hemiparkinsonism , 1995, The Journal of pharmacy and pharmacology.

[21]  Milan Randić Characterization of Molecular Attributes , 1998 .

[22]  N. Bodor,et al.  Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. , 1999, Journal of medicinal chemistry.

[23]  H. Schlicht,et al.  Synthesis, opioid receptor affinity, and enzymatic hydrolysis of sterically hindered morphine 3-esters. , 1996, Journal of pharmaceutical sciences.

[24]  R. Borchardt,et al.  A Comparison of the Bioconversion Rates and the Caco-2 Cell Permeation Characteristics of Coumarin-Based Cyclic Prodrugs and Methylester-Based Linear Prodrugs of RGD Peptidomimetics , 1998, Pharmaceutical Research.

[25]  S. Frokjaer,et al.  Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Yunjin Jung,et al.  Synthesis and properties of N-nicotinoyl-2-(5-fluorouracil-1-yl)-D,L-glycine ester as a prodrug of 5-fluorouracil for rectal administration. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  Zheng-gen Liao,et al.  Prodrugs of scutellarin: ethyl, benzyl and N,N-diethylglycolamide ester synthesis, physicochemical properties, intestinal metabolism and oral bioavailability in the rats. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  E. Santucci,et al.  L-dopa- and dopamine-(R)-alpha-lipoic acid conjugates as multifunctional codrugs with antioxidant properties. , 2006, Journal of medicinal chemistry.

[29]  R. Angell,et al.  Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. , 2000, Journal of medicinal chemistry.

[30]  H. Bundgaard,et al.  Stereoselective Enzymatic Hydrolysis of Various Ester Prodrugs of Ibuprofen and Flurbiprofen in Human Plasma , 1992, Pharmaceutical Research.

[31]  P. Crooks,et al.  Synthesis and stability of two indomethacin prodrugs. , 2006, Bioorganic & medicinal chemistry letters.

[32]  K. Engle,et al.  Short-Chain Alkyl Esters of L-Dopa as Prodrugs for Rectal Absorption , 1989, Pharmaceutical Research.

[33]  M. Hassan,et al.  Synthesis, chemical and enzymatic hydrolysis, and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility , 2001, The Journal of pharmacy and pharmacology.

[34]  C. Larsen,et al.  Bioreversible quaternary N-acyloxymethyl derivatives of the tertiary amines bupivacaine and lidocaine--synthesis, aqueous solubility and stability in buffer, human plasma and simulated intestinal fluid. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  N. Bodor,et al.  Soft Drugs Based on Hydrocortisone: The Inactive Metabolite Approach and Its Application to Steroidal Antiinflammatory Agents , 1999, Pharmaceutical Research.

[36]  N Bodor,et al.  Soft drug design: General principles and recent applications , 2000, Medicinal research reviews.

[37]  F. G. Njoroge,et al.  Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue. , 2008, Bioorganic & medicinal chemistry.

[38]  E. Falch,et al.  Pilocarpine prodrugs. II. Synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters. , 1986, Journal of pharmaceutical sciences.

[39]  N. Bodor,et al.  Soft drugs. 21. Design and evaluation of soft analogs of propantheline. , 1996, Journal of pharmaceutical sciences.

[40]  P. Crooks,et al.  Human Skin Permeation of Branched-Chain 3-O-Alkyl Ester and Carbonate Prodrugs of Naltrexone , 2005, Pharmaceutical Research.

[41]  R. Moreira,et al.  Acyloxymethyl as a drug protecting group. Part 6: N-acyloxymethyl- and N-[(aminocarbonyloxy)methyl]sulfonamides as prodrugs of agents containing a secondary sulfonamide group. , 2000, Bioorganic & medicinal chemistry.

[42]  E. Falch,et al.  Water-Soluble, Solution-Stable, and Biolabile N-Substituted (Aminomethyl)benzoate Ester Prodrugs of Acyclovir , 1991, Pharmaceutical Research.

[43]  R. Moreira,et al.  Acyloxymethyl as a Drug Protecting Group: Part 4. The Hydrolysis of Tertiary Amidomethyl Ester Prodrugs of Carboxylic Acid Agents , 1997, Pharmaceutical Research.

[44]  A. Tropsha,et al.  Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. , 2003, Journal of medicinal chemistry.

[45]  M. Karelson Molecular descriptors in QSAR/QSPR , 2000 .

[46]  R. Borchardt,et al.  Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. , 2005, Journal of pharmaceutical sciences.

[47]  P. Yogeeswari,et al.  Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. , 2004, Bioorganic & medicinal chemistry letters.

[48]  S. Frokjaer,et al.  N-terminal 4-imidazolidinone prodrugs of Leu-enkephalin: synthesis, chemical and enzymatic stability studies. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[49]  P. Yogeeswari,et al.  Synthesis of zidovudine prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[50]  S. Ho,et al.  IN VITRO AND IN VIVO EVALUATION OF THE METABOLISM AND PHARMACOKINETICS OF SEBACOYL DINALBUPHINE , 2005, Drug Metabolism and Disposition.

[51]  E. Menegatti,et al.  Synthesis and Study of 5′-Ester Prodrugs of N6-Cyclopentyladenosine, a Selective A1 Receptor Agonist , 2001, Pharmaceutical Research.

[52]  Robert D. Clark,et al.  OptiSim: An Extended Dissimilarity Selection Method for Finding Diverse Representative Subsets , 1997, J. Chem. Inf. Comput. Sci..

[53]  S. Frokjaer,et al.  Model prodrugs for the intestinal oligopeptide transporter: model drug release in aqueous solution and in various biological media. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[54]  J. Iley,et al.  Triazene Drug Metabolites: Part 15. Synthesis and Plasma Hydrolysis of Anticancer Triazenes Containing Amino Acid Carriers , 1998, Pharmaceutical Research.

[55]  R. Moreira,et al.  Aminocarbonyloxymethyl Ester Prodrugs of Flufenamic Acid and Diclofenac: Suppressing the Rearrangement Pathway in Aqueous Media , 2007, Archiv der Pharmazie.

[56]  H. Bundgaard,et al.  Facile plasma‐catalysed degradation of penicillin alkyl esters but with no liberation of the parent penicillin , 1988, The Journal of pharmacy and pharmacology.

[57]  H. Lennernäs,et al.  Stability and in vitro metabolism of dipeptide model prodrugs with affinity for the oligopeptide transporter. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[58]  Y. Rojanasakul,et al.  Characterization of Mefenamic Acid-Guaiacol Ester: Stability and Transport Across Caco-2 Cell Monolayers , 2002, Pharmaceutical Research.

[59]  Søren Balling Engelsen,et al.  Prediction of in vitro metabolic stability of calcitriol analogs by QSAR , 2003, J. Comput. Aided Mol. Des..

[60]  R. Borchardt,et al.  In Vitro Stability and In Vivo Pharmacokinetic Studies of a Model Opioid Peptide, H-Tyr-d-Ala-Gly-Phe-d-Leu-OH (DADLE), and Its Cyclic Prodrugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[61]  Ian H. Witten,et al.  Data mining: practical machine learning tools and techniques, 3rd Edition , 1999 .